摘要
目的:探讨吉西他滨联合顺铂(GP)、吉西他滨联合洛铂(GL)髂内动脉化疗栓塞(TACE)治疗肌层浸润性膀胱尿路上皮癌的疗效。方法:选取2019年1月至2021年1月该院收治的浸润性膀胱尿路上皮癌患者104例,采用随机数字表法分为观察组和对照组。两组患者均接受TACE治疗,对照组52例患者予以GP方案,观察组52例患者予以GL方案。比较两组患者的临床疗效和不良反应,治疗前后肿瘤标志物、炎症反应和免疫功能。结果:观察组患者的疾病控制率为71.15%(37/52),高于对照组的51.92%(27/52),差异有统计学意义(P<0.05)。观察组患者治疗后血清糖类抗原125、癌胚抗原水平低于对照组,血清白细胞介素(IL)6、IL-1β和肿瘤坏死因子α水平低于对照组,CD3^(+)、CD4^(+)和CD4^(+)/CD8^(+)水平高于对照组,差异均有统计学意义(P<0.05)。观察组患者骨髓抑制、白细胞减少和恶心呕吐的发生率分别为11.54%(6/52)、38.46%(20/52)和26.92%(14/52),低于对照组的26.92%(14/52)、59.62%(31/52)和48.08%(25/52),差异均有统计学意义(P<0.05)。结论:GL方案TACE治疗能改善浸润性膀胱尿路上皮癌患者肿瘤标志物水平,缓解炎症反应,调节免疫功能,减少不良反应,临床疗效确切。
OBJECTIVE:To probe into the efficacy of internal iliac artery transcatheter arterial chemoembolization(TACE)with gemcitabine combined with cisplatin(GP)and gemcitabine combined with lobaplatin(GL)in the treatment of muscle invasive bladder urothelial carcinoma.METHODS:A total of 104 patients with invasive bladder urothelial carcinoma admitted into the hospital from Jan.2019 to Jan.2021 were extracted to be divided into the observation group and the control group via the random number table.Two groups were treated with TACE,52 patients in the control group were treated with GP regimen,and 52 patients in the observation group received GL regimen.The clinical efficacy and adverse drug reactions,tumor markers,inflammatory response and immune function before and after treatment were compared between two groups.RESULTS:The disease control rate of the observation group was 71.15%(37/52),higher than 51.92%(27/52)of the control group,with statistically significant differences(P<0.05).After treatment,the serum levels of CA125 and CEA in the observation group were lower than those in the control group,the serum levels of interleukin(IL)6,IL-1βand TNF-αwere lower than those of the control group,and CD3^(+),CD4^(+)and CD4^(+)/CD8^(+)were higher than those of the control group,the differences were statistically significant(P<0.05).The incidences of bone marrow suppression,leukopenia,nausea and vomiting in the observation group were respectively 11.54%(6/52),38.46%(20/52)and 26.92%(14/52),lower than 26.92%(14/52),59.62%(31/52)and 48.08%(25/52)in the control group,the differences were statistically significant(P<0.05).CONCLUSIONS:GL regimen TACE treatment can improve the level of tumor markers in patients with invasive bladder urothelial carcinoma,alleviate inflammatory response,regulate immune function and reduce adverse drug reactions with definite clinical efficacy.
作者
丁劲
曾建勇
刘颖
周柏村
林文静
唐观林
DING Jin;ZENG Jianyong;LIU Ying;ZHOU Baicun;LIN Wenjing;TANG Guanlin(Dept.of Pharmacy,Chengdu Sixth People’s Hospital,Chengdu 610051,China;Dept.of Urology,Chengdu Sixth People’s Hospital,Chengdu 610051,China)
出处
《中国医院用药评价与分析》
2022年第11期1353-1356,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
肌层浸润性膀胱尿路上皮癌
吉西他滨
顺铂
洛铂
肿瘤标志物
炎症反应
免疫功能
Muscle invasive bladder urothelial carcinoma
Gemcitabine
Cisplatin
Lobaplatin
Tumor marker
Inflammatory response
Immune function
